STEADYMED LTD.
STEADYMED LTD. (STDY): 1 pipeline candidate · ~13 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
13.0 months
0% dilution
Lead: BLA Filed
1 candidate
N/A
N/A
A transparent, data-derived signal for STEADYMED LTD.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$21.1M
Quarterly Burn
$4.9M
Runway
13.0 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| trevyent | BLA Filed |
Frequently asked questions
How many drug candidates are in STEADYMED LTD.'s pipeline?
STEADYMED LTD. (STDY) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is STEADYMED LTD.'s lead drug candidate?
STEADYMED LTD.'s most advanced tracked candidate is trevyent (BLA Filed) for pulmonary arterial hypertension.
What is STEADYMED LTD.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, STEADYMED LTD. has approximately 13.0 months of cash runway.
Who is the CEO of STEADYMED LTD.?
Jonathan Rigby is the chief executive officer of STEADYMED LTD. (STDY).
Get the full picture on STEADYMED LTD.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.